- Home
- DSM vs XOMA Comparison
DSM vs XOMA Comparison
Compare DSM & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- XOMA
- Stock Information
- Founded
- DSM 1989
- XOMA 1981
- Country
- DSM United States
- XOMA United States
- Employees
- DSM N/A
- XOMA N/A
- Industry
- DSM Investment Managers
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- XOMA Health Care
- Exchange
- DSM Nasdaq
- XOMA Nasdaq
- Market Cap
- DSM 270.9M
- XOMA 250.1M
- IPO Year
- DSM N/A
- XOMA N/A
- Fundamental
- Price
- DSM $5.51
- XOMA $21.18
- Analyst Decision
- DSM
- XOMA Strong Buy
- Analyst Count
- DSM 0
- XOMA 3
- Target Price
- DSM N/A
- XOMA $59.67
- AVG Volume (30 Days)
- DSM 161.7K
- XOMA 26.2K
- Earning Date
- DSM 01-01-0001
- XOMA 05-08-2025
- Dividend Yield
- DSM 3.97%
- XOMA N/A
- EPS Growth
- DSM N/A
- XOMA N/A
- EPS
- DSM N/A
- XOMA N/A
- Revenue
- DSM N/A
- XOMA $28,487,000.00
- Revenue This Year
- DSM N/A
- XOMA $14.22
- Revenue Next Year
- DSM N/A
- XOMA $34.01
- P/E Ratio
- DSM N/A
- XOMA N/A
- Revenue Growth
- DSM N/A
- XOMA 498.72
- 52 Week Low
- DSM $4.69
- XOMA $18.35
- 52 Week High
- DSM $6.05
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- DSM 37.11
- XOMA 54.26
- Support Level
- DSM $5.28
- XOMA $20.00
- Resistance Level
- DSM $5.77
- XOMA $21.55
- Average True Range (ATR)
- DSM 0.10
- XOMA 1.20
- MACD
- DSM -0.02
- XOMA 0.29
- Stochastic Oscillator
- DSM 37.70
- XOMA 79.27
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.